OX40

OX40-targeted agent

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OX40, covering 2023-05-24 to 2023-05-24. Get the full timeline:

Most recent: Clinical Trial Update: OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

See pricing